Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
#2023USCHA was a Love Letter to Black Women—and a joyous family reunion for the HIV community. [VIDEOS]
The company will resume development of islatravir for HIV treatment but abandons monthly oral PrEP.
Islatravir, a long-acting antiretroviral, has hit a snag after clinical trial participants experienced falling white blood cell counts.
Keytruda can activate T cells that harbor latent HIV, a possible step toward a functional cure.
Studies of islatravir are put on hold after participants experience declining CD4 and lymphocyte counts.
#2021USCHA—the U.S. Conference on HIV/AIDS—may have ended, but you can still experience it via these pics, tweets and videos.
Molnupiravir reduces severe illness and death, but it must be started within days after developing symptoms.
Another vaccine, from Novavax, was 89% effective in a U.K. trial, but both were less potent against the South African coronavirus mutation.
The HIV regimen failed only a few study participants.
AIDS United speaks with Deondre Moore about promoting U=U among African Americans via the “Owning HIV” campaign.
Survey findings from the “Owning HIV” campaign show the need for proactive education.
MK-8507, a long-acting NNRTI, will be tested in a weekly regimen with islatravir.
This is according to a three-year study in which people switched from a stable HIV regimen to Delstrigo.
None of the people who experienced virologic failure on regimens containing the experimental drug had a viral load of 200 or higher.
A mid-stage trial showed the combo suppressed HIV, was well tolerated and resulted in a low rate of virologic failure.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.